Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study

NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative...
May 28, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Senior Management to Present at BIO 2019

- Chaim Lebovits, President & CEO Corporate Presentation, June 4, 2019 - - Ralph Kern MD, MHSc, Chief Medical Officer & Chief Operating Officer Round Table Panelist, June 4, 2019 - NEW...
May 13, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London

NEW YORK and LONDON, May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced...
May 10, 2019 17:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update

Highlights Scientific Advances and Continued Progress in NurOwn® ALS Phase 3 Trial and Progressive MS Phase 2 Trial; Expansion of the proprietary cellular technology platform NEW YORK,...
April 30, 2019 04:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases

NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced...
March 28, 2019 04:30 ET | Source: BrainStorm Cell Therapeutics Inc.

Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting

NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
March 26, 2019 06:30 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Grant of an additional New European Patent for NurOwn®

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
March 14, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS

NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
March 07, 2019 04:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm to Host Business Update Conference Call

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
February 22, 2019 07:30 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study

NEW YORK and CLEVELAND, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...